A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.

Affiliation

Department of Oncology, University Hospital of Modena and Reggio Emilia, Modena, Italy. [Email]

Abstract

The advent of immune checkpoint inhibitors (ICIs) has considerably expanded the armamentarium against non-small cell lung cancer (NSCLC) contributing to reshaping treatment paradigms in the advanced disease setting. While promising tissue- and plasma-based biomarkers are under investigation, no reliable predictive factor is currently available to aid in treatment selection.

Keywords

Immunotherapy,Lung cancer,Nivolumab,Nomogram,Prognostic factors,

OUR Recent Articles